BioClinica,
Inc. (NASDAQ: BIOC), a global provider of clinical trial management
services, today announced the appointment of Garry D. Johnson as Senior
Vice President and Chief Technology Officer (CTO), a newly created
position.
“Adding Garry to the BioClinica team is an
important benchmark in our company history. The CTO position creates a
global-level perspective focused on technology innovation that is
expected to maintain BioClinicas competitive edge and expand our
reputation for providing best-in-class solutions.”
BioClinica adds the position of CTO to its senior management staff to
support its growth initiatives and emphasis on current and future
technologies across the organization. Mr. Johnson will lead the
companys global technology strategy, including developing and
implementing BioClinicas technology plan, overseeing technology
investments and ensuring that operational efficiencies are maximized.
Mr. Johnson comes to BioClinica with more than 15 years experience
leading international technology organizations through the strategic
development and execution of business-aligned IT plans. He most recently
served as Senior Vice President and Global Chief Technology officer for
Dendrite International, Inc. (now Cegedim Dendrite), a global provider
of sales, compliance and clinical solutions to the pharmaceutical and
life sciences industry. At Dendrite Mr. Johnson led a team of 900
technology professionals on three continents tasked with delivering
software and services. Among his accomplishments was the development of
a new CRM solution that gained broad customer acceptance with six
migrations in the first 12 months. Prior to Dendrite, Mr. Johnson held
leadership positions at Boron Lepore, Inc. (now Cardinal Health) and
AlliedSignal, Inc. (now Honeywell).
Mr. Johnson has had a longstanding commitment to the New Jersey
Technology Council (NJTC). He was honored with NJTCs first CIO of the
Year award in 2005. He has also served on NJTCS CIO Advisory Board. In
addition, under his leadership, Dendrite was recognized by Gartner
Research Report as Best in Class user support for Dendrite, SAP, and
Siebel users. Mr. Johnson earned a bachelors degree in management from
Fairfield University in Fairfield, CT.
Garry is a proven technology leader with the skills to advance
BioClinicas industry-leading position in clinical trial management
services. His wealth of industry knowledge and experience make him a
valued asset to BioClinica and our global customer base, said Mark
Weinstein, CEO of BioClinica. Adding Garry to the BioClinica team is an
important benchmark in our company history. The CTO position creates a
global-level perspective focused on technology innovation that is
expected to maintain BioClinicas competitive edge and expand our
reputation for providing best-in-class solutions.
Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog,
and on Twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated,
technology-enhanced clinical trial management services. BioClinica
supports pharmaceutical and medical device innovation with imaging core
lab, internet image transport, electronic data capture, interactive
voice and web response, clinical trial management and clinical supply
chain design and optimization solutions. BioClinica services maximize
efficiency and manageability throughout all phases of the clinical trial
process. With more than 20 years of experience and over 2,000 successful
trials to date, BioClinica has supported the clinical development of
many new medicines from early phase trials through final approval.
BioClinica operates state-of-the-art, regulatory-body-compliant imaging
core labs on two continents, and supports worldwide eClinical and data
management services from offices in the United States, Europe and Asia.
For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are forward-looking
statements intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995. In
particular, the Companys statements regarding trends in the marketplace
and potential future results are examples of such forward-looking
statements. The forward-looking statements include risks and
uncertainties, including, but not limited to, the consummation and the
successful integration of current and proposed acquisitions, the timing
of projects due to the variability in size, scope and duration of
projects, estimates and guidance made by management with respect to the
Companys financial results, backlog, critical accounting policies,
regulatory delays, clinical study results which lead to reductions or
cancellations of projects, and other factors, including general economic
conditions and regulatory developments, not within the Companys control.
The factors discussed herein and expressed from time to time in the
Companys filings with the Securities and Exchange Commission could
cause actual results and developments to be materially different from
those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this press
release and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstance.
You should review the Companys filings, especially risk factors
contained in the Form 10-K and the recent Form 10-Q.
&p class= bwtextaligncen

Source: Business Wire